跳到主要内容
Learn Motion
探索课程产品能力价格

下载 Learn Motion

用手机扫描二维码,下载 App。

App Store

扫码从 App Store 下载 Learn Motion打开商店页面

Google Play

扫码从 Google Play 下载 Learn Motion打开商店页面
登录
Learn Motion

How AI Predicts Drug Failure Before Human Trials

1Why Predicting Drug Failure Matters2What AI Learns From: The Data Behind Predictions3How AI Turns Data Into a Failure Prediction4Judging Whether a Prediction Can Be Trusted5How Predictions Are Used in Real Drug Development
How AI Turns Data Into a Failure Prediction

Reading a Risk Score

2 / 3
Read the scale from left to right, low risk to high. The marker sits where it does because of the comparison group shown beside it: drugs with a similar profile that already have a known outcome. A high position means most of those comparable drugs failed. It does not mean this drug has that exact chance of failing, because this drug is not one of those drugs. Notice also that the marker's meaning depends on how many comparable drugs there are. When the comparison group is thin, the position is less trustworthy, even if it looks the same.
0:00 / 0:00

The output of a failure-prediction model is usually a number between 0 and 1, or a position on a scale from low to high risk. It is easy to read that number as a probability that this particular drug will fail. That reading is too strong.

The score is built from the historical record. It reflects how often drugs that looked like this one — similar structure, similar assay profile, similar position in the evidence — went on to fail in the past. A score of 0.7 means that among the comparable drugs in the training history, roughly seven in ten failed. It does not mean this drug has a seventy percent chance of failing, because this drug is not a random draw from that history; it is a specific candidate with its own biology.

Two further qualifications follow. First, the score is only as meaningful as the comparison group behind it: if few past drugs resemble this candidate, the score rests on thin evidence and should be treated as uncertain. Second, the scale is not calibrated across different models or different disease areas. A 0.7 from one model and a 0.7 from another are not the same claim, and neither transfers cleanly to a disease area the training data barely covered.

What the score is genuinely good for is ranking. If candidate A scores higher than candidate B on the same model and the same evidence, the model is saying A resembles past failures more than B does. That comparative reading survives the caveats above far better than any absolute interpretation.

上一页2 / 3下一页

Learn Motion

生成课程,认真学会。

运营方:Wuhan Daoyin Technology Co., Ltd.

联系我们: [email protected]
隐私政策用户服务协议

© 2026 Learn Motion